AR022687A1 - Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos. - Google Patents

Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos.

Info

Publication number
AR022687A1
AR022687A1 ARP990106455A ARP990106455A AR022687A1 AR 022687 A1 AR022687 A1 AR 022687A1 AR P990106455 A ARP990106455 A AR P990106455A AR P990106455 A ARP990106455 A AR P990106455A AR 022687 A1 AR022687 A1 AR 022687A1
Authority
AR
Argentina
Prior art keywords
derivatives
alkyl
quinoxalin
disorders
manufacture
Prior art date
Application number
ARP990106455A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR022687A1 publication Critical patent/AR022687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP990106455A 1998-12-17 1999-12-16 Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos. AR022687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21347198A 1998-12-17 1998-12-17

Publications (1)

Publication Number Publication Date
AR022687A1 true AR022687A1 (es) 2002-09-04

Family

ID=22795247

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106455A AR022687A1 (es) 1998-12-17 1999-12-16 Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos.

Country Status (18)

Country Link
EP (1) EP1140940A1 (no)
JP (1) JP2002532504A (no)
KR (1) KR20010108025A (no)
CN (1) CN1240701C (no)
AR (1) AR022687A1 (no)
AU (1) AU3123400A (no)
BR (1) BR9916326A (no)
CA (1) CA2351385A1 (no)
CZ (1) CZ20012193A3 (no)
EA (1) EA200100671A1 (no)
HU (1) HUP0104773A3 (no)
IL (1) IL143323A0 (no)
NO (1) NO20013001L (no)
NZ (1) NZ512765A (no)
PL (1) PL348815A1 (no)
SK (1) SK8192001A3 (no)
WO (1) WO2000035922A1 (no)
ZA (1) ZA200104598B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
EP1337518B1 (en) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
WO2002059127A2 (en) * 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
WO2002074746A1 (fr) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
BR0210238A (pt) 2001-06-01 2004-07-20 Alcon Inc Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
JP2004535418A (ja) 2001-06-01 2004-11-25 アルコン，インコーポレイテッド ピラノインダゾールおよび緑内障治療への使用
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
EP1513831B1 (en) 2002-06-19 2010-01-06 Biovitrum AB (publ) Novel compounds, their use and preparation
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
EP1581221B1 (en) 2002-12-19 2011-05-18 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CA2529750A1 (en) * 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
JP2008514662A (ja) * 2004-09-30 2008-05-08 エフ．ホフマン−ラ ロシュ アーゲー ベンゾオキサジン及びキノキサリン誘導体並びに使用
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
KR101110199B1 (ko) 2009-05-18 2012-03-14 한국화학연구원 피페라진-퀴놀린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
EP2531485B1 (en) 2010-02-04 2019-04-24 The Board of Trustees of the University of Illionis Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2012099952A2 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2016123164A1 (en) 2015-01-29 2016-08-04 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US4089958A (en) * 1976-12-20 1978-05-16 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof
US4203987A (en) * 1979-05-21 1980-05-20 American Home Products Corporation 3-[Pyridinylalkyl and piperidinylalkyl]-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-ones
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
EP0539209A1 (en) * 1991-10-24 1993-04-28 The Upjohn Company Benzo-isoquinoline derivatives and analogs and their use in therapeutics
AU4547796A (en) * 1995-02-03 1996-08-21 Sankyo Company Limited Hexahydropyrazinoquinoline derivatives

Also Published As

Publication number Publication date
PL348815A1 (en) 2002-06-17
JP2002532504A (ja) 2002-10-02
HUP0104773A2 (hu) 2002-04-29
ZA200104598B (en) 2002-09-05
CZ20012193A3 (cs) 2001-12-12
KR20010108025A (ko) 2001-12-07
IL143323A0 (en) 2002-04-21
NO20013001D0 (no) 2001-06-15
CN1240701C (zh) 2006-02-08
SK8192001A3 (en) 2001-12-03
AU3123400A (en) 2000-07-03
BR9916326A (pt) 2001-10-02
WO2000035922A1 (en) 2000-06-22
HUP0104773A3 (en) 2004-10-28
NO20013001L (no) 2001-06-15
NZ512765A (en) 2003-10-31
CA2351385A1 (en) 2000-06-22
EP1140940A1 (en) 2001-10-10
CN1330652A (zh) 2002-01-09
EA200100671A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
AR022687A1 (es) Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos.
BR0211455B1 (pt) sistema adequado como catalisador, e, processos para a preparaÇço do mesmo, de misturas de mononitrilas c5 mono-olefÍnicas, de uma dinitrila e de adipodinitrila.
BR0206561A (pt) Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto
BR9808254A (pt) Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
UY28150A1 (es) Agentes terapeuticos
AR031202A1 (es) Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR033383A1 (es) Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR067475A1 (es) Antagonistas no basico s del receptor de la hormona concentradora de melanina 1
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
ES2150671T3 (es) Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
UY27503A1 (es) Nuevos derivados de piperazina
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
DE69724259D1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
DE60004671D1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
AR035587A1 (es) Un compuesto derivado de la triptamina y sus analogos, y una composicion farmaceutica que lo contiene
BRPI0411823A (pt) derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico
AR026222A1 (es) Compuestos derivados de acido antranilico
DE69825879D1 (de) Pharmazeutische zusammensetzungen welche aryl-substituierte olefinische amin-verbindungen enthalten
ES2160240T3 (es) Benzamidas para el tratamiento de desordenes neurodegenerativos.
Hawkes N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal